Literature DB >> 1544125

Age-linked prognostic categorization based on a new histologic grading system of neuroblastomas. A clinicopathologic study of 211 cases from the Pediatric Oncology Group.

V V Joshi1, A B Cantor, G Altshuler, E W Larkin, J S Neill, J J Shuster, C T Holbrook, F A Hayes, R Nitschke, M H Duncan.   

Abstract

Histologic sections (minimum of four sections per patient) from 211 patients with neuroblastoma were reviewed. The tumors were resected before therapy, which was standardized according to age and stage. Low mitotic rate (MR) (less than or equal to ten per ten high-power fields) and calcification emerged as the most significant prognostic features after statistical analysis by stepwise log-rank tests (P less than 0.0001 and P = 0.0065, respectively). Histologic Grades 1, 2, and 3 were defined on the basis of the presence of both, any one, or none of these two prognostic features, respectively (Grade 3 had absence of low MR, i.e., these tumors had high MR [greater than ten per ten high-power fields]). Statistically significant differences in survival were observed in the grades after adjusting for age and stage (P less than 0.001). The degree of differentiation, although significant by itself, was no longer significant after adjusting for the grades. Age groups (less than or equal to 1 versus greater than 1 year of age), which also emerged as an independent prognostic feature (P less than 0.001), were linked with the grades to define two risk groups as follows: (1) a low-risk (LR) group consisting of patients in both age groups with Grade 1 tumors and patients 1 year of age or younger with Grade 2 tumors and (2) a high-risk (HR) group consisting of patients older than 1 year of age with Grade 2 tumors and patients in both age groups with Grade 3 tumors. The difference in survival between LR (160 cases) and HR groups (51 cases) was statistically significant (P less than 0.001). Concordance between these LR and HR groups and the Shimada classification was observed in 84% of cases. The new histologic grading system has the following advantages: (1) use of familiar terminology and histologic features in the grading system and (2) relative ease of assessment because the degree of differentiation does not need to be determined. The grading system should be tested on a new data set with an appropriate histologic sample of similar size to confirm these results.

Entities:  

Mesh:

Year:  1992        PMID: 1544125     DOI: 10.1002/1097-0142(19920415)69:8<2197::aid-cncr2820690829>3.0.co;2-x

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  14 in total

1.  Prognostic value of the International Neuroblastoma Pathology Classification in Neuroblastoma (Schwannian stroma-poor) and comparison with other prognostic factors: a study of 182 cases from the Spanish Neuroblastoma Registry.

Authors:  Octavio Burgues; Samuel Navarro; Rosa Noguera; Antonio Pellín; Amparo Ruiz; Victoria Castel; Antonio Llombart-Bosch
Journal:  Virchows Arch       Date:  2006-08-29       Impact factor: 4.064

2.  Pineal ganglioneuroblastoma in an adult.

Authors:  M Tanaka; S Shibui; K Nomura; Y Nakanishi
Journal:  J Neurooncol       Date:  1999-09       Impact factor: 4.130

3.  Adult-onset adrenal ganglioneuroblastoma - Bone metastasis two years after surgery: report of a case.

Authors:  Shugo Mizuno; Taku Iida; Shiro Fujita
Journal:  Surg Today       Date:  2010-04-28       Impact factor: 2.549

4.  HUlip, a human homologue of unc-33-like phosphoprotein of Caenorhabditis elegans; Immunohistochemical localization in the developing human brain and patterns of expression in nervous system tumors.

Authors:  Yoon-La Choi; Chong Jai Kim; Tatsuya Matsuo; Carlo Gaetano; Rita Falconi; Yeon-Lim Suh; Seok-Hyung Kim; Young Kee Shin; Seong Hoe Park; Je Geun Chi; Carol J Thiele
Journal:  J Neurooncol       Date:  2005-05       Impact factor: 4.130

5.  Clinico-epidemiology of neuroblastoma in north east Egypt: A 5-year multicenter study.

Authors:  Youssef Al-Tonbary; Mohamed Badr; Ahmed Mansour; Usama El Safy; Shebl Saeed; Tamer Hassan; Rasha Elashery; Rofida Nofal; Ahmad Darwish
Journal:  Oncol Lett       Date:  2015-06-08       Impact factor: 2.967

6.  Prognostic significance of the proliferative activity in neuroblastoma.

Authors:  P Rudolph; T Lappe; B Hero; F Berthold; R Parwaresch; D Harms; D Schmidt
Journal:  Am J Pathol       Date:  1997-01       Impact factor: 4.307

7.  Prognostic factors including neoadjuvant chemotherapy in Mexican children with neuroblastoma.

Authors:  Alberto Olaya-Vargas; Roberto Rivera-Luna; Rocío Cárdenas-Cardós; Araceli Castellanos Toledo; Oscar Alberto Pérez González; Julieta Robles Castro; Carlos Calderón Elvir
Journal:  Clin Transl Oncol       Date:  2005 Jan-Feb       Impact factor: 3.405

8.  Demonstration of apoptosis in neuroblastoma and its relationship to tumour regression.

Authors:  H Koizumi; M Wakisaka; K Nakada; T Takakuwa; T Fujioka; N Yamate; T Uchikoshi
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

9.  Association of neurotrophin receptor expression and differentiation in human neuroblastoma.

Authors:  J C Hoehner; L Olsen; B Sandstedt; D R Kaplan; S Påhlman
Journal:  Am J Pathol       Date:  1995-07       Impact factor: 4.307

Review 10.  Neuroblastoma stage IV-S.

Authors:  T D Miale; K Kirpekar
Journal:  Med Oncol       Date:  1994       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.